Harel Insurance Investments & Financial Services Ltd. lessened its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 7.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,812 shares of the company's stock after selling 1,705 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.'s holdings in Cencora were worth $5,510,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of COR. Exchange Traded Concepts LLC boosted its holdings in shares of Cencora by 4.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company's stock worth $307,000 after buying an additional 48 shares during the last quarter. Dynamic Advisor Solutions LLC boosted its stake in Cencora by 6.4% in the first quarter. Dynamic Advisor Solutions LLC now owns 1,535 shares of the company's stock worth $427,000 after buying an additional 93 shares in the last quarter. GAMMA Investing LLC boosted its stake in Cencora by 57.0% in the first quarter. GAMMA Investing LLC now owns 5,748 shares of the company's stock worth $1,598,000 after buying an additional 2,087 shares in the last quarter. Westpac Banking Corp boosted its stake in shares of Cencora by 13.5% during the fourth quarter. Westpac Banking Corp now owns 21,895 shares of the company's stock valued at $4,919,000 after purchasing an additional 2,596 shares during the period. Finally, Golden State Wealth Management LLC lifted its stake in Cencora by 157.6% in the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock worth $47,000 after acquiring an additional 104 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.
Cencora Price Performance
Shares of NYSE COR traded up $5.06 during midday trading on Friday, hitting $296.23. The stock had a trading volume of 614,990 shares, compared to its average volume of 1,504,083. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The company has a market capitalization of $57.42 billion, a PE ratio of 34.37, a P/E/G ratio of 1.47 and a beta of 0.57. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. The stock has a 50 day simple moving average of $291.12 and a 200-day simple moving average of $267.23.
Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.80 earnings per share. On average, sell-side analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.
Cencora Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.74%. Cencora's payout ratio is currently 25.52%.
Analyst Ratings Changes
Several research firms recently commented on COR. Robert W. Baird lifted their price objective on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Bank of America boosted their target price on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Citigroup boosted their price objective on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. Morgan Stanley set a $288.00 target price on Cencora in a report on Tuesday, April 15th. Finally, Wells Fargo & Company upgraded Cencora from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Cencora presently has a consensus rating of "Moderate Buy" and a consensus target price of $306.33.
Check Out Our Latest Research Report on COR
Insider Transactions at Cencora
In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the completion of the sale, the chief executive officer directly owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the transaction, the chairman directly owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,127 shares of company stock valued at $9,812,296. Insiders own 10.80% of the company's stock.
Cencora Company Profile
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
